Tremfya (guselkumab), developed by Johnson & Johnson, is a monoclonal antibody that selectively targets the p19 subunit of interleukin-23. Polaris Market Research values the Tremfya market at USD 4.2 billion in 2025, with a projected CAGR of 7.40% from 2026 to 2034 and USD 7.99 billion by 2034. This article focuses on how label expansion, access support, and competition are shaping the outlook.
Expanding Beyond Dermatology and Rheumatology
Tremfya was initially approved by the FDA for moderate-to-severe psoriasis in 2017, and its label extended to active joint disease in 2020. It has since moved into gastroenterology: the FDA approved it for moderately to severely active ulcerative colitis in September 2024 and for Crohn's disease in March 2025, when it became the first IL-23 inhibitor available in subcutaneous and intravenous formulations for adults with the condition. The EMA approved both bowel indications in May 2025. The QUASAR and GALAXI Phase 3 trials supported these expansions, which the report says reflect Johnson & Johnson's broader immunology strategy. In May 2026, the company announced an FDA label expansion making Tremfya the only IL-23 inhibitor proven to slow structural joint damage progression in adults with active psoriatic arthritis.
Improving Access for Patients
Because biologics are expensive, patient support programs play a vital role in demand. Through Janssen CarePath, eligible patients in the United States can receive copay assistance, reimbursement support, and information on alternate funding options. For those without insurance, the Johnson & Johnson Patient Assistance Foundation offers Tremfya at no cost when income and residency criteria are met. The report says these programs improve adherence and help reduce disparities in care.
Distribution Is Becoming More Digital
Hospital pharmacies lead distribution today, but online pharmacies are anticipated to register the highest growth rate. The report attributes this to patient preference for convenience and home delivery, expanding telehealth and remote prescription services, and advances in cold chain logistics and packaging that make at-home delivery more feasible.
Competition and Restraints
Competition is strong. Alternatives include other IL-23 inhibitors such as risankizumab, IL-17 inhibitors such as secukinumab, TNF-alpha inhibitors such as adalimumab, and small-molecule therapies such as PDE4 or JAK inhibitors. Differentiation hinges on onset of action, sustained response, long-term safety, and dosing frequency. Restraints include the high cost of treatment, high market-entry barriers such as cold-chain logistics and stringent regulatory data requirements, and biosimilar pressure: Bio-Thera Solutions, Alvotech, and Samsung Bioepis are advancing IL-23 inhibitor biosimilars ahead of patent expiry.
Browse In-depth Market Research Report:
https://www.polarismarketresearch.com/industry-analysis/tremfya-market
Cost and Reimbursement Considerations
The high cost of guselkumab limits access for low-income patients, and coverage differs by payer and region. Regulatory approval increases indication availability but does not ensure equal reimbursement. Distribution cost structures also differ: hospital pharmacies carry higher administration and monitoring costs, while growth in digital channels reflects a shift toward lower-cost, convenience-driven access. Geographic expansion is another focus, with Asia Pacific, Latin America, and parts of the Middle East described as untapped opportunities, although local regulatory pathways and pricing dynamics vary widely.
Pipeline Developments
Johnson & Johnson is advancing JNJ-2113, an oral IL-23 receptor antagonist in Phase 3 for psoriasis that offers a needle-free alternative to injectable biologics, and TLL-018, a dual TYK2/JAK1 inhibitor licensed from Suzhou Connect Biopharma and in Phase 2 trials.
Key Player
The report identifies Johnson & Johnson as the key player in the market:
- Johnson & Johnson
Conclusion
The Tremfya market is being shaped by new gastroenterology indications, stronger patient support, and evolving distribution channels, alongside rising biosimilar and competitive pressure. Access programs and digital distribution may widen the patient base, while pricing and patent dynamics will test the pace of growth through 2034. The report expects demand for targeted biologic therapies, rising autoimmune disease prevalence, and expanding access to specialty medicines to support the market.
More Trending Latest Reports By Polaris Market Research:
Clinical Trial Outsourcing Market